To the full analysis
REGENXBIO stock: growth
RGNXREGENXBIO reported $170.44M in revenue for fiscal 2025, up 104.5% on the prior year, up 2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
32%
per year from 2013 to 2025, per share 3.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 2.0% | 36.5% | 32.0% |
| Revenue per share | −4.4% | 14.9% | 3.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $6.09M | −$5.39M | −$3.01M |
| 2014 | $6.12M | −$4M | −$2.4M |
| 2015 | $7.59M | −$22.81M | −$23.04M |
| 2016 | $4.59M | −$62.97M | −$56.71M |
| 2017 | $10.39M | −$73.17M | −$65.15M |
| 2018 | $218.51M | $99.94M | $91.37M |
| 2019 | $35.23M | −$94.73M | −$119.43M |
| 2020 | $154.57M | −$111.25M | −$80.93M |
| 2021 | $470.35M | $127.84M | $134.7M |
| 2022 | $112.72M | −$280.32M | −$238.21M |
| 2023 | $90.24M | −$263.49M | −$228.37M |
| 2024 | $83.33M | −$227.1M | −$175.56M |
| 2025 | $170.44M | −$193.88M | −$126.38M |
Revenue by segment
How REGENXBIO Inc. makes its money and how that has shifted. Names are as the company reports them.
- License and Service$156.3M92%
- Service$14.2M8%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| License and Service | $156.27M | 91.7% |
| Service | $14.17M | 8.3% |
| Total revenue | $170.44M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.